Efficacy and Safety of Tirzepatide Once Weekly Versus Placebo After an Intensive Lifestyle Program in Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double Blind, Placebo-Controlled Trial (SURMOUNT-3)

This is a study of tirzepatide in participants with obesity. The purpose of this study is to learn more about how tirzepatide maintains body weight or adds to weight loss after an intensive lifestyle modification program. The study will last about 2 years (29 visits).

本研究针对肥胖受试者开展替尔泊肽（tirzepatide）相关研究。本研究旨在深入探究在强化生活方式干预方案实施后，替尔泊肽在维持体质量或进一步减轻体质量方面的作用效果。本研究周期约为2年，共计包含29次随访访视。